{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:28:50Z","timestamp":1789025330753,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Korean Society of Interventional Cardiology","award":["2021-04"],"award-info":[{"award-number":["2021-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07729-7","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:16:47Z","timestamp":1754043407000},"page":"923-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Moderate-Intensity Atorvastatin and Ezetimibe Combination Therapy Versus High-Intensity Atorvastatin in Patients with Angina Pectoris who Underwent Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"40","author":[{"given":"Seo Young","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Hyung","family":"Doh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-817X","authenticated-orcid":false,"given":"Sung Woo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"1","key":"7729_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"25","key":"7729_CR2","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","journal-title":"Circulation"},{"issue":"34","key":"7729_CR3","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"issue":"11","key":"7729_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047","journal-title":"Eur J Prev Cardiol"},{"key":"7729_CR5","doi-asserted-by":"publisher","unstructured":"Nelson AJ, Haynes K, Shambhu S et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.048","DOI":"10.1016\/j.jacc.2022.02.048"},{"issue":"17","key":"7729_CR6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment aetiology and management. Eur Heart J. 2015;36(17):1012\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehv043","journal-title":"Eur Heart J"},{"key":"7729_CR7","doi-asserted-by":"publisher","unstructured":"Mach F, Ray KK, Wiklund O et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehy182","DOI":"10.1093\/eurheartj\/ehy182"},{"issue":"8","key":"7729_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries. JAMA Cardiol. 2017;2(8):890\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2017.0911","journal-title":"JAMA Cardiol"},{"key":"7729_CR9","doi-asserted-by":"publisher","first-page":"114111","DOI":"10.1016\/j.ejmech.2022.114111","volume":"230","author":"R Zhang","year":"2022","unstructured":"Zhang R, Liu W, Zeng J, et al. Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. Eur J Med Chem. 2022;230:114111. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114111","journal-title":"Eur J Med Chem"},{"issue":"15","key":"7729_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1161\/01.cir.0000034044.95911.dc","volume":"106","author":"T Sudhop","year":"2002","unstructured":"Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943\u20138. https:\/\/doi.org\/10.1161\/01.cir.0000034044.95911.dc","journal-title":"Circulation"},{"issue":"4","key":"7729_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10557-014-6534-9","volume":"28","author":"B Zafrir","year":"2014","unstructured":"Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther. 2014;28(4):361\u201377. https:\/\/doi.org\/10.1007\/s10557-014-6534-9","journal-title":"Cardiovasc Drugs Ther"},{"issue":"25","key":"7729_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"issue":"10349","key":"7729_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00916-3","journal-title":"Lancet"},{"issue":"9","key":"7729_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jamacardio.2023.2222","volume":"8","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Cha JJ, Choi WG, et al. Moderate-intensity statin with ezetimibe combination therapy vs high-intensity statin monotherapy in patients at very high risk of atherosclerotic cardiovascular disease: a post hoc analysis from the racing randomized clinical trial. JAMA Cardiol. 2023;8(9):853\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2023.2222","journal-title":"JAMA Cardiol"},{"key":"7729_CR15","doi-asserted-by":"publisher","first-page":"101933","DOI":"10.1016\/j.eclinm.2023.101933","volume":"58","author":"JI Park","year":"2023","unstructured":"Park JI, Lee SJ, Hong BK, et al. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial. EClinicalMedicine. 2023;58:101933. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101933","journal-title":"EClinicalMedicine"},{"key":"7729_CR16","doi-asserted-by":"publisher","unstructured":"Kim BG, Lee SJ, Lee YJ et al. Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis. Sci Rep. 2023;13(1):20157. https:\/\/doi.org\/10.1038\/s41598-023-47505-x","DOI":"10.1038\/s41598-023-47505-x"},{"key":"7729_CR17","doi-asserted-by":"publisher","first-page":"117373","DOI":"10.1016\/j.atherosclerosis.2023.117373","volume":"386","author":"B Lee","year":"2023","unstructured":"Lee B, Hong SJ, Rha SW, et al. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: a post-hoc analysis of the RACING randomized trial. Atherosclerosis. 2023;386:117373. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117373","journal-title":"Atherosclerosis"},{"issue":"14","key":"7729_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jacc.2023.02.007","volume":"81","author":"SH Lee","year":"2023","unstructured":"Lee SH, Lee YJ, Heo JH, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis. J Am Coll Cardiol. 2023;81(14):1339\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.007","journal-title":"J Am Coll Cardiol"},{"key":"7729_CR19","doi-asserted-by":"publisher","unstructured":"Kim J, Kang D, Park H et al. Moderate-intensity statins plus ezetimibe vs. high-intensity statins after coronary revascularization: a cohort study. Cardiovasc Drugs Ther. 2023;37(1):141\u201350. https:\/\/doi.org\/10.1007\/s10557-021-07256-1","DOI":"10.1007\/s10557-021-07256-1"},{"issue":"5","key":"7729_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","volume":"82","author":"SJ Lee","year":"2023","unstructured":"Lee SJ, Joo JH, Park S, et al. Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2023;82(5):401\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2023.05.042","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7729_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41598-024-51310-5","volume":"14","author":"JY Jang","year":"2024","unstructured":"Jang JY, Kim S, Cho J, et al. Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study. Sci Rep. 2024;14(1):838. https:\/\/doi.org\/10.1038\/s41598-024-51310-5","journal-title":"Sci Rep"},{"issue":"18","key":"7729_CR22","doi-asserted-by":"publisher","first-page":"e030414","DOI":"10.1161\/JAHA.123.030414","volume":"12","author":"J Lewek","year":"2023","unstructured":"Lewek J, Niedziela J, Desperak P, et al. Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS data. J Am Heart Assoc. 2023;12(18):e030414. https:\/\/doi.org\/10.1161\/JAHA.123.030414","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"7729_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/ehjcvp\/pvad083","volume":"10","author":"SJ Lee","year":"2025","unstructured":"Lee SJ, Joo JH, Park S, et al. Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability. Eur Heart J Cardiovasc Pharmacother. 2025;10(8):676\u201385. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad083","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"1","key":"7729_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12933-024-02498-3","volume":"23","author":"EH Choo","year":"2024","unstructured":"Choo EH, Moon D, Choi IJ, et al. Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention. Cardiovasc Diabetol. 2024;23(1):396. https:\/\/doi.org\/10.1186\/s12933-024-02498-3","journal-title":"Cardiovasc Diabetol"},{"key":"7729_CR25","doi-asserted-by":"publisher","unstructured":"Kim K, Bang WD, Han K et al. Comparison of the effects of high-intensity statin therapy with moderate-intensity statin and ezetimibe combination therapy on major adverse cardiovascular events in patients with acute myocardial infarction: a nationwide cohort study. J Lipid Atheroscler. 2021;10(3):291\u2013302. https:\/\/doi.org\/10.12997\/jla.2021.10.3.291","DOI":"10.12997\/jla.2021.10.3.291"},{"issue":"1","key":"7729_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jamainternmed.2015.7110","volume":"176","author":"DW Shin","year":"2016","unstructured":"Shin DW, Cho B, Guallar E. Korean National Health Insurance database. JAMA Intern Med. 2016;176(1):138. https:\/\/doi.org\/10.1001\/jamainternmed.2015.7110","journal-title":"JAMA Intern Med"},{"issue":"48","key":"7729_CR27","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1093\/eurheartj\/ehx585","volume":"38","author":"MK Kim","year":"2017","unstructured":"Kim MK, Han K, Kim HS, et al. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. Eur Heart J. 2017;38(48):3560\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehx585","journal-title":"Eur Heart J"},{"issue":"6","key":"7729_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"issue":"8","key":"7729_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718","journal-title":"Eur Heart J"},{"issue":"14","key":"7729_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehx566","journal-title":"Eur Heart J"},{"issue":"1","key":"7729_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12944-018-0880-8","volume":"17","author":"C Ai","year":"2018","unstructured":"Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis. 2018;17(1):239. https:\/\/doi.org\/10.1186\/s12944-018-0880-8","journal-title":"Lipids Health Dis"},{"issue":"10263","key":"7729_CR32","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","volume":"396","author":"B Gencer","year":"2020","unstructured":"Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(20)32332-1","journal-title":"Lancet"},{"issue":"12","key":"7729_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397. https:\/\/doi.org\/10.1001\/jama.2016.13985","journal-title":"JAMA"},{"issue":"6","key":"7729_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3904\/kjim.2023.243","volume":"38","author":"J Lee","year":"2023","unstructured":"Lee J, Lee SH. Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia. Korean J Intern Med. 2023;38(6):797\u2013809. https:\/\/doi.org\/10.3904\/kjim.2023.243","journal-title":"Korean J Intern Med"},{"issue":"5","key":"7729_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66(5):495\u2013507. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7729_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.carrev.2016.11.010","volume":"18","author":"M Hougaard","year":"2017","unstructured":"Hougaard M, Hansen HS, Thayssen P, et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med. 2017;18(2):110\u20137. https:\/\/doi.org\/10.1016\/j.carrev.2016.11.010","journal-title":"Cardiovasc Revasc Med"},{"issue":"5","key":"7729_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.hlc.2015.10.012","volume":"25","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao X, Li L, et al. Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ. 2016;25(5):459\u201365. https:\/\/doi.org\/10.1016\/j.hlc.2015.10.012","journal-title":"Heart Lung Circ"},{"issue":"2","key":"7729_CR38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.4238\/2014.April.3.10","volume":"13","author":"P Luo","year":"2014","unstructured":"Luo P, Li L, Wang LX, et al. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Genet Mol Res. 2014;13(2):2377\u201384. https:\/\/doi.org\/10.4238\/2014.April.3.10","journal-title":"Genet Mol Res"},{"issue":"4","key":"7729_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneph.2012.33","volume":"8","author":"M Epstein","year":"2012","unstructured":"Epstein M, Vaziri ND. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol. 2012;8(4):214\u201323. https:\/\/doi.org\/10.1038\/nrneph.2012.33","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"7729_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727\u201349. https:\/\/doi.org\/10.1038\/s41581-018-0072-9","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"7729_CR41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cpt.1859","volume":"108","author":"YC Lin","year":"2020","unstructured":"Lin YC, Lai TS, Wu HY, et al. Effects and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease: a systematic review and meta-analysis. Clin Pharmacol Ther. 2020;108(4):833\u201343. https:\/\/doi.org\/10.1002\/cpt.1859","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07729-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:27Z","timestamp":1778649687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7729"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07729-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"27 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Helsinki Declaration and was approved by the institutional review board of Inje University Ilsan Paik Hospital (IRB no. 2021\u201312-006).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The institutional review board of Inje University Ilsan Paik Hospital confirmed that the requirement for obtaining informed consent was not applicable because this study used anonymous administrative claim data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}